James Sabry at #JPM24 (Brian Benton Photography)
May 28, 2024 04:09 AM EDTUpdated 06:08 AM
People
Bioregnum

Af­ter 14 years call­ing part­ner­ing shots at Genen­tech/Roche, James Sabry is head­ed back in­to the biotech fray

James Sabry, the long­time doyen of biotech deal­mak­ers from his glob­al perch at Roche/Genen­tech, is jump­ing to the US biotech scene.

The Basel-based phar­ma gi­ant …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times